Bio-Matrix Scientific's Research Subsidiary, Entest BioMedical, Inc., Files Stem Cell Therapy Patent Application for Treatment of COPD.Adipose adipose /ad·i·pose/ (ad´i-pos) 1. fatty. 2. the fat present in the cells of adipose tissue. ad·i·pose adj. Of, relating to, or composed of animal fat; fatty. Stem Cells to Be Used SAN DIEGO -- Bio-Matrix Scientific Group, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BMSN BMSN Seaman, Boatswain's Mate Striker (Naval Rating) ) announced today its majority owned subsidiary, Entest BioMedical unit (OTCBB: ENTB ENTB Extended Navy Testbed ), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. (COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) ). BMSN is excited with the progress achieved by Entest BioMedical, Inc. (OTCBB: ENTB) in identifying diseases it believes will be treatable through Stem Cell Therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs . Chronic Obstructive Pulmonary Disease is a major health disorder that appears to be treatable through adipose derived stem cell therapy. COPD is a group of lung inflammatory diseases which includes both emphysema and chronic obstructive bronchitis affecting more than 5 million Americans each year. It is the fourth leading cause of death in America, impacting more than 5 million Americans, resulting in more than 120,000 deaths in the USA per year. Currently, this disease is treated in similar fashion to asthma, utilizing inhalers and /or oxygen therapy. These methods are not solutions to the disease but merely provide the patient with greater level of comfort. Steven Josephs, PhD. noted, "The approach is intended at the very least to alleviate the chronic inflammation in COPD. This is done by using agents known to coax adult stem cells that are delivered to the diseased lung tissue (blood monocyte monocyte /mono·cyte/ (mon´o-sit) a mononuclear, phagocytic leukocyte, 13µ to 25µ in diameter, with an ovoid or kidney-shaped nucleus, and azurophilic cytoplasmic granules. cells) to release cytokines (biologically active molecules) which in addition to the anti-inflammatory effects may actually promote the regeneration of functional lung tissue." The goal of Entest BioMedical, Inc. is to develop a stem cell therapy that reverses the effects of COPD on the respiratory system. The Company is working with Dr. Feng Lin, its Scientific Director and Steven Josephs, PhD in developing this stem cell treatment. About Bio-Matrix Scientific Group Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. Follow the Company's progress on Twitter A Web site and service that lets users send short text messages from their cellphones to a group of friends. Launched in 2006, Twitter (www.twitter.com) was designed for people to broadcast their current activities and thoughts. : http://twitter.com/BMSN1. About Entest BioMedical Inc.: Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, cancer treatment, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Entest BioMedical website is www.EntestBio.com. Disclaimer This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion